Pharma Co. Reports Positive Data for Leukemia Combination Therapy

Research Report
  ()
Recently, Syros Pharmaceuticals Inc. announced positive data for its Leukemia Combination Therapy, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Drugs Show Anti-Cancer Effects on Myeloma Cells

Research Report
  ()
These positive results bode well for the biopharma's two polyamine inhibitors as potential treatments for multiple myeloma, noted a ROTH Capital Markets report.
Tags:  Biotechnology / Pharmaceuticals

Antibodies from Vaccine Remain Two Years Out

Research Report
  ()
This was shown in recent clinical trial results of a biotech's single-dose vaccine against chikungunya evaluated in adults, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Massachusetts Biotech Plummets as Skin Cancer Trial Fails

  ()
In recent news, Massachusetts clinical-stage biotechnology company Replimune Group Inc. revealed its latest clinical trial did not meet the endpoints needed to call it a success. With this, the stock has plummeted.
Tags:  Biotechnology / Pharmaceuticals

Pharma Co.'s Partnership a Key Validation

Research Report
  ()
Recently, Arcus Biosciences Inc. announced a partnership with Exelixis Inc., which may be the key to validating the company, noted WedBush analysts in a December 4 report.
Tags:  Biotechnology / Pharmaceuticals

Biotech Announces New Responder in Breast Cancer Trail

Research Report
  ()
Recently, BriaCell Therapeutics Corp. announced a new exceptional responder in its Phase 2 study evaluating the company's off-the-shelf personalized immunotherapy, noted H.C. Wainwright analyst Emily Bodnar.
Tags:  Biotechnology / Pharmaceuticals

Biotech Receives First Approval; Drug Now Available

Research Report
  ()
Recently, SpringWorks Therapeutics Inc. announced FDA approval of OGSIVEO (nirogacestat) for treating progressing desmoid tumors (DT) in adult patients based on Phase 3 DeFi trial results, noted H.C. Wainwright & Co. analysts Robert Burns and Dr. Raghuram Selvaraju.
Tags:  Biotechnology / Pharmaceuticals

Encouraging Early Data For Biotech's Cancer Therapies

Research Report
  ()
In a recent corporate update, Purple Biotech Ltd. reported positive interim Phase 1/2 data for NT219 and accelerated enrollment for CM24, noted H.C. Wainwright analyst Emily Bodnar.
Tags:  Biotechnology / Pharmaceuticals

Strong Early Launch Metrics for Biotech's Skin Disease Drug

Research Report
  ()
Oren Livnat of H.C. Wainwright & Co. sees over 240% upside potential for Verrica Pharmaceuticals based on the early commercial success of its recently launched skin disease treatment.
Tags:  Biotechnology / Pharmaceuticals

Arizona Biotech Advances Multiple Cell Therapies

Research Report
  ()
Roth MKM has a US$30 price target on this biotech company based on progress across its regenerative medicine pipeline, including upcoming Phase 1/2 data.
Tags:  Biotechnology / Pharmaceuticals

Massachusetts Biotech Advances Novel Cytokine Therapies

Research Report
  ()
Wedbush sees over 300% upside for Werewolf stock based on early clinical success for its PREDATOR platform and pipeline, according to a WedBush research note.
Tags:  Biotechnology / Pharmaceuticals

Texas Biotech Exceeds Alzheimer's Trial Enrollment Target

Research Report
  ()
This Texas-based biotech company's enrollment in its two pivotal Phase 3 trials evaluating lead drug candidate simufilam for Alzheimer's disease surpassed initial enrollment targets, noted H.C. Wainwright analyst Vernon Bernardino.
Tags:  Biotechnology / Pharmaceuticals

Massachusetts Biotech Presents Catalysts Into 2024

Research Report
  ()
Cambridge, Massachusetts-based iTeos Therapeutics presented multiple upcoming catalysts into 2024 after reporting Q3 results, noted Wedbush analyst Dr. David Nierengarten.
Tags:  Biotechnology / Pharmaceuticals

Expert Shares Thoughts on Six Stocks

Contributed Opinion
  ()
Chris Temple of The National Investors shares a detailed report on stocks from the life science to the energy sector to tell you which he believes are Buys and which you should sell.
Tags:  UraniumGoldSilverBiotechnology / Pharmaceuticals

Biopharma Acquires Royalty on Approved Diabetes Drug

Research Report
  ()
This is one of the California-based company's many transactions resulting from its royalty monetization strategy, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Survey Results Positive for New HAE Drug

Research Report
  ()
Most responding physicians, all with hereditary angioedema patients, indicated an "above average" impression of the treatment's safety and efficacy data, noted an Oppenheimer report.
Tags:  Biotechnology / Pharmaceuticals

Expert Investing Ideas

"RHT is rated an Immediate Buy here."

–Clive Maund, CliveMaund.com


Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Safety Profile of New IL-2 Molecule Better Than Like Drugs'

Research Report
  ()
First clinical data of this investigational interleukin-2 cytokine show it lacks the degree and rates of adverse events typically seen with treatments of this kind, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Firm To Present Trial Results Update at SITC Meeting

Research Report
  ()
Data will be reviewed from Part B, the dose expansion portion, of the Phase 1 study of a new TGF-β1 isoform inhibitor in advanced cancer, noted a Wedbush report.
Tags:  Biotechnology / Pharmaceuticals

Add Back Positions in This Biotech

Contributed Opinion
  ()
Chris Temple of The National Investor shares one stock he believes is currently a Buy, as a gross overreaction caused sell-offs.
Tags:  Biotechnology / Pharmaceuticals

Biotech to Advance New Type 1 Diabetes Drug Into Clinic

Research Report
  ()
Dosing of the first patient is expected in Q4/23 in this Phase 1 trial to be done in Australia, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Approval Likely in U.S., EU for New Drug for Prader-Willi

Research Report
  ()
Despite recent positive clinical trials, the biopharma behind this treatment remains undervalued presenting a buying opportunity, noted an Oppenheimer report.
Tags:  Biotechnology / Pharmaceuticals